Molecular Signatures of Cancer Stemness Characterize the Correlations with Prognosis and Immune Landscape and Predict Risk Stratification in Pheochromocytomas and Paragangliomas

Background: Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy. Method: The tumor stemness is closely relate...

Full description

Saved in:
Bibliographic Details
Published inBioengineering (Basel) Vol. 12; no. 3; p. 219
Main Authors Li, Lei, Liu, Shuangyu, Guo, Zeqi, Tang, Yueming, Zhang, Yue, Qiu, Ling, Li, Yue
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 21.02.2025
MDPI
Subjects
Online AccessGet full text
ISSN2306-5354
2306-5354
DOI10.3390/bioengineering12030219

Cover

Abstract Background: Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy. Method: The tumor stemness is closely related to the heterogeneous growth of tumor, metastasis, and drug-resistance, and mRNA expression-based stemness indices (mRNAsi) could reflect tumor stemness. This was calculated based on OCLR machine learning algorithm and PPGLs patients’ TCGA RNAseq data. The relationship between clinical, molecular, and tumor microenvironment (TME) features and tumor stemness was analyzed through the hub genes that best captured the stem cell characteristics of PPGLs using weighted gene co-expression network analysis (WGCNA), Cox, and LASSO regression analysis. Results: Our study found that metastatic PPGLs had higher mRNAsi scores, suggesting the degree of tumor stemness could affect metastasis and progression. HRAS, CSDE1, NF1, RET, and VHL-mutant subtypes displayed significant difference in stemness expression. Patients were divided into stemness high-score and low-score subtypes. High-score PPGLs displayed the more unfavorable prognosis compared with low-score, associated with their immune-suppressive features, manifested as low macrophages M1 infiltration and downregulated expression of immune checkpoints. Furthermore, from the viewpoint of stemness features, we established a reliable prognostic for PPGLs, which has the highest AUC value (0.908) in the field so far. And this could stratify PPGLs patients into high-risk and low-risk subtypes, showing the significant differences in prognosis, underlying mechanisms correlated with specific molecular alterations, biological processes activation, and TME. Notably, high immune infiltration and tumor neoantigen in low-risk patients and further resulted in more responsive to immunotherapy. Conclusion: We indicated that tumor stemness could act as the potential biomarker for metastasis or prognosis of PPGLs, and integrated multi-data sources, analyzed valuable stemness-related genes, developed and verified a novel stemness scoring system to predict prognosis and guide the choice of treatment strategies.
AbstractList Background: Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy. Method: The tumor stemness is closely related to the heterogeneous growth of tumor, metastasis, and drug-resistance, and mRNA expression-based stemness indices (mRNAsi) could reflect tumor stemness. This was calculated based on OCLR machine learning algorithm and PPGLs patients’ TCGA RNAseq data. The relationship between clinical, molecular, and tumor microenvironment (TME) features and tumor stemness was analyzed through the hub genes that best captured the stem cell characteristics of PPGLs using weighted gene co-expression network analysis (WGCNA), Cox, and LASSO regression analysis. Results: Our study found that metastatic PPGLs had higher mRNAsi scores, suggesting the degree of tumor stemness could affect metastasis and progression. HRAS, CSDE1, NF1, RET, and VHL-mutant subtypes displayed significant difference in stemness expression. Patients were divided into stemness high-score and low-score subtypes. High-score PPGLs displayed the more unfavorable prognosis compared with low-score, associated with their immune-suppressive features, manifested as low macrophages M1 infiltration and downregulated expression of immune checkpoints. Furthermore, from the viewpoint of stemness features, we established a reliable prognostic for PPGLs, which has the highest AUC value (0.908) in the field so far. And this could stratify PPGLs patients into high-risk and low-risk subtypes, showing the significant differences in prognosis, underlying mechanisms correlated with specific molecular alterations, biological processes activation, and TME. Notably, high immune infiltration and tumor neoantigen in low-risk patients and further resulted in more responsive to immunotherapy. Conclusion: We indicated that tumor stemness could act as the potential biomarker for metastasis or prognosis of PPGLs, and integrated multi-data sources, analyzed valuable stemness-related genes, developed and verified a novel stemness scoring system to predict prognosis and guide the choice of treatment strategies.
Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy. The tumor stemness is closely related to the heterogeneous growth of tumor, metastasis, and drug-resistance, and mRNA expression-based stemness indices (mRNAsi) could reflect tumor stemness. This was calculated based on OCLR machine learning algorithm and PPGLs patients' TCGA RNAseq data. The relationship between clinical, molecular, and tumor microenvironment (TME) features and tumor stemness was analyzed through the hub genes that best captured the stem cell characteristics of PPGLs using weighted gene co-expression network analysis (WGCNA), Cox, and LASSO regression analysis. Our study found that metastatic PPGLs had higher mRNAsi scores, suggesting the degree of tumor stemness could affect metastasis and progression. , , , , and -mutant subtypes displayed significant difference in stemness expression. Patients were divided into stemness high-score and low-score subtypes. High-score PPGLs displayed the more unfavorable prognosis compared with low-score, associated with their immune-suppressive features, manifested as low macrophages M1 infiltration and downregulated expression of immune checkpoints. Furthermore, from the viewpoint of stemness features, we established a reliable prognostic for PPGLs, which has the highest AUC value (0.908) in the field so far. And this could stratify PPGLs patients into high-risk and low-risk subtypes, showing the significant differences in prognosis, underlying mechanisms correlated with specific molecular alterations, biological processes activation, and TME. Notably, high immune infiltration and tumor neoantigen in low-risk patients and further resulted in more responsive to immunotherapy. We indicated that tumor stemness could act as the potential biomarker for metastasis or prognosis of PPGLs, and integrated multi-data sources, analyzed valuable stemness-related genes, developed and verified a novel stemness scoring system to predict prognosis and guide the choice of treatment strategies.
Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy.BACKGROUNDPheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor development prompted more research on diagnosis, prognosis prediction, and immunotherapy.The tumor stemness is closely related to the heterogeneous growth of tumor, metastasis, and drug-resistance, and mRNA expression-based stemness indices (mRNAsi) could reflect tumor stemness. This was calculated based on OCLR machine learning algorithm and PPGLs patients' TCGA RNAseq data. The relationship between clinical, molecular, and tumor microenvironment (TME) features and tumor stemness was analyzed through the hub genes that best captured the stem cell characteristics of PPGLs using weighted gene co-expression network analysis (WGCNA), Cox, and LASSO regression analysis.METHODThe tumor stemness is closely related to the heterogeneous growth of tumor, metastasis, and drug-resistance, and mRNA expression-based stemness indices (mRNAsi) could reflect tumor stemness. This was calculated based on OCLR machine learning algorithm and PPGLs patients' TCGA RNAseq data. The relationship between clinical, molecular, and tumor microenvironment (TME) features and tumor stemness was analyzed through the hub genes that best captured the stem cell characteristics of PPGLs using weighted gene co-expression network analysis (WGCNA), Cox, and LASSO regression analysis.Our study found that metastatic PPGLs had higher mRNAsi scores, suggesting the degree of tumor stemness could affect metastasis and progression. HRAS, CSDE1, NF1, RET, and VHL-mutant subtypes displayed significant difference in stemness expression. Patients were divided into stemness high-score and low-score subtypes. High-score PPGLs displayed the more unfavorable prognosis compared with low-score, associated with their immune-suppressive features, manifested as low macrophages M1 infiltration and downregulated expression of immune checkpoints. Furthermore, from the viewpoint of stemness features, we established a reliable prognostic for PPGLs, which has the highest AUC value (0.908) in the field so far. And this could stratify PPGLs patients into high-risk and low-risk subtypes, showing the significant differences in prognosis, underlying mechanisms correlated with specific molecular alterations, biological processes activation, and TME. Notably, high immune infiltration and tumor neoantigen in low-risk patients and further resulted in more responsive to immunotherapy.RESULTSOur study found that metastatic PPGLs had higher mRNAsi scores, suggesting the degree of tumor stemness could affect metastasis and progression. HRAS, CSDE1, NF1, RET, and VHL-mutant subtypes displayed significant difference in stemness expression. Patients were divided into stemness high-score and low-score subtypes. High-score PPGLs displayed the more unfavorable prognosis compared with low-score, associated with their immune-suppressive features, manifested as low macrophages M1 infiltration and downregulated expression of immune checkpoints. Furthermore, from the viewpoint of stemness features, we established a reliable prognostic for PPGLs, which has the highest AUC value (0.908) in the field so far. And this could stratify PPGLs patients into high-risk and low-risk subtypes, showing the significant differences in prognosis, underlying mechanisms correlated with specific molecular alterations, biological processes activation, and TME. Notably, high immune infiltration and tumor neoantigen in low-risk patients and further resulted in more responsive to immunotherapy.We indicated that tumor stemness could act as the potential biomarker for metastasis or prognosis of PPGLs, and integrated multi-data sources, analyzed valuable stemness-related genes, developed and verified a novel stemness scoring system to predict prognosis and guide the choice of treatment strategies.CONCLUSIONWe indicated that tumor stemness could act as the potential biomarker for metastasis or prognosis of PPGLs, and integrated multi-data sources, analyzed valuable stemness-related genes, developed and verified a novel stemness scoring system to predict prognosis and guide the choice of treatment strategies.
Audience Academic
Author Qiu, Ling
Liu, Shuangyu
Guo, Zeqi
Zhang, Yue
Li, Yue
Li, Lei
Tang, Yueming
AuthorAffiliation 2 Department of Clinical Laboratories, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China; liushuangyuyu@126.com (S.L.); sxycgzq@126.com (Z.G.); 18317009638@163.com (Y.Z.)
1 Department of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China; lilei30@pumch.cn (L.L.); tangyuem1@126.com (Y.T.)
3 State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China
AuthorAffiliation_xml – name: 2 Department of Clinical Laboratories, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China; liushuangyuyu@126.com (S.L.); sxycgzq@126.com (Z.G.); 18317009638@163.com (Y.Z.)
– name: 3 State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China
– name: 1 Department of Laboratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, Beijing 100730, China; lilei30@pumch.cn (L.L.); tangyuem1@126.com (Y.T.)
Author_xml – sequence: 1
  givenname: Lei
  surname: Li
  fullname: Li, Lei
– sequence: 2
  givenname: Shuangyu
  surname: Liu
  fullname: Liu, Shuangyu
– sequence: 3
  givenname: Zeqi
  surname: Guo
  fullname: Guo, Zeqi
– sequence: 4
  givenname: Yueming
  surname: Tang
  fullname: Tang, Yueming
– sequence: 5
  givenname: Yue
  surname: Zhang
  fullname: Zhang, Yue
– sequence: 6
  givenname: Ling
  orcidid: 0000-0002-0734-8144
  surname: Qiu
  fullname: Qiu, Ling
– sequence: 7
  givenname: Yue
  orcidid: 0000-0002-1129-4572
  surname: Li
  fullname: Li, Yue
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40150683$$D View this record in MEDLINE/PubMed
BookMark eNqNkl1v0zAUhiM0xMbYX5gsccNNhz_yeYWmakClIio-rq0T5zhxSexiJ0zlX_EPcdsxVrQLFCmx3rzvc3yO_Tw5sc5iklwyeiVERV_XxqFtjUX0xraMU0E5q54kZ1zQfJaJLD15sD5NLkJYU0qZ4BnP02fJaUpZRvNSnCW_Prge1dSDJ59Na2GcPAbiNJmDVRjFEQeLIZB5Bx7UGCv-RDJ2SObOe-xhNM4GcmvGjqy8a60LJhCwDVkMw2SRLOM6KNjgXlx5bIwayScTvkW2j3Ft1B5CjCWrDp3qvBuc2o5ugANpFSu3YNve7KQXyVMNfcCLu-958vXtzZf5-9ny47vF_Ho5UxnPxvjOOUtVwdOmzoumyFnFFVSoSyGgEILF_mka58EFKMGVzosKKE810KrUeS3Ok8WB2zhYy403A_itdGDkXnC-leBHo3qURa5Q61KLKmepFqJuOACjKFIomKp3rOLAmuwGtrfQ9_dARuXuTOXjZxqTbw7JzVQP2Ci0cWj90XaO_1jTydb9kCyG43ZYJLy6I3j3fcIwysEEhX0PFt0UpGAlT0vKWBatL_-xrt3kbZzyzsVEHGkl_rpaiL0bq10srHZQeV0KXpa8qtLounrEFZ8GB6PifdYm6keBy4ed3rf4565GQ34wKO9C8Kj_d4a_ASCgBj0
Cites_doi 10.3389/fimmu.2024.1478922
10.1186/s13073-019-0638-6
10.3390/cancers17010066
10.1007/s12022-021-09675-0
10.1186/s13059-017-1349-1
10.1186/s12943-018-0858-1
10.3389/fimmu.2022.796606
10.1007/s12022-022-09704-6
10.1158/0008-5472.CAN-18-0689
10.1210/jc.2018-01968
10.1038/nature25501
10.1186/s13046-018-0978-x
10.3390/ijms22137239
10.1158/0008-5472.CAN-17-0307
10.1038/nmeth.3337
10.3390/genes13060993
10.3390/cancers14030467
10.1002/jcp.27740
10.1186/s12967-023-04683-6
10.1016/j.omto.2022.10.005
10.1016/j.ccell.2017.01.001
10.1210/clinem/dgaa982
10.3390/jcm10010088
10.1016/j.semcancer.2018.06.006
10.1097/MPA.0b013e3181ebb4f0
10.1210/jc.2014-1498
10.1182/bloodadvances.2018015685
10.1186/s13073-014-0095-1
10.1002/jcb.27646
10.3390/cancers14040917
10.1016/j.cell.2018.03.034
10.1007/978-1-0716-0327-7_17
10.1155/2016/9012369
10.1038/s41392-021-00484-9
10.1016/j.ccell.2023.09.011
10.3389/fonc.2023.1139990
10.1186/s13059-016-1070-5
10.1038/s41591-018-0136-1
10.1530/ERC-21-0392
ContentType Journal Article
Copyright COPYRIGHT 2025 MDPI AG
2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 by the authors. 2025
Copyright_xml – notice: COPYRIGHT 2025 MDPI AG
– notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 by the authors. 2025
DBID AAYXX
CITATION
NPM
8FE
8FG
8FH
ABJCF
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
L6V
LK8
M7P
M7S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PTHSS
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.3390/bioengineering12030219
DatabaseName CrossRef
PubMed
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Journals
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
ProQuest Technology Collection (LUT)
Natural Science Collection
ProQuest One
ProQuest Central
ProQuest Central Student
SciTech Premium Collection (Proquest)
ProQuest Engineering Collection
Biological Sciences
Biological science database
Engineering Database (Proquest)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database (Proquest)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
Technology Collection
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Engineering Collection
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
Engineering Collection
Engineering Database
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Technology Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Materials Science & Engineering Collection
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList CrossRef
Publicly Available Content Database

PubMed

MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 2306-5354
ExternalDocumentID oai_doaj_org_article_76ceff8f39614f33bd2aa10e34a71cbb
10.3390/bioengineering12030219
PMC11939611
A832882994
40150683
10_3390_bioengineering12030219
Genre Journal Article
GroupedDBID 53G
5VS
8FE
8FG
8FH
AAFWJ
AAYXX
ABDBF
ABJCF
ACUHS
ADBBV
AFKRA
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
CCPQU
CITATION
GROUPED_DOAJ
HCIFZ
HYE
IAO
IHR
INH
ITC
KQ8
L6V
LK8
M7P
M7S
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQGLB
PROAC
PTHSS
RPM
NPM
ABUWG
AZQEC
DWQXO
GNUQQ
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
PUEGO
5PM
ADTOC
IPNFZ
RIG
UNPAY
ID FETCH-LOGICAL-c525t-c56214c724db67d76192ca9ef833a73310680452623ac32cf679a024fa098f6b3
IEDL.DBID DOA
ISSN 2306-5354
IngestDate Fri Oct 03 12:51:02 EDT 2025
Sun Oct 26 03:23:45 EDT 2025
Tue Sep 30 17:04:51 EDT 2025
Fri Sep 05 17:53:39 EDT 2025
Fri Jul 25 11:49:46 EDT 2025
Mon Oct 20 22:45:04 EDT 2025
Mon Oct 20 16:54:39 EDT 2025
Tue Apr 01 01:21:43 EDT 2025
Thu Oct 16 04:43:45 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords pheochromocytoma and paragangliomas
tumor microenvironment
prognostic model
tumor stemness
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c525t-c56214c724db67d76192ca9ef833a73310680452623ac32cf679a024fa098f6b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-0734-8144
0000-0002-1129-4572
OpenAccessLink https://doaj.org/article/76ceff8f39614f33bd2aa10e34a71cbb
PMID 40150683
PQID 3181356293
PQPubID 2055440
ParticipantIDs doaj_primary_oai_doaj_org_article_76ceff8f39614f33bd2aa10e34a71cbb
unpaywall_primary_10_3390_bioengineering12030219
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11939611
proquest_miscellaneous_3182480115
proquest_journals_3181356293
gale_infotracmisc_A832882994
gale_infotracacademiconefile_A832882994
pubmed_primary_40150683
crossref_primary_10_3390_bioengineering12030219
PublicationCentury 2000
PublicationDate 2025-02-21
PublicationDateYYYYMMDD 2025-02-21
PublicationDate_xml – month: 02
  year: 2025
  text: 2025-02-21
  day: 21
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Bioengineering (Basel)
PublicationTitleAlternate Bioengineering (Basel)
PublicationYear 2025
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Malta (ref_9) 2018; 173
Sainz (ref_40) 2016; 2016
Newman (ref_11) 2015; 12
Racle (ref_12) 2020; 2120
Granberg (ref_26) 2021; 106
Luo (ref_29) 2018; 2
ref_13
Fishbein (ref_8) 2017; 31
ref_34
Finotello (ref_14) 2019; 11
ref_33
ref_32
ref_30
Marquardt (ref_22) 2018; 53
Najafi (ref_28) 2019; 120
Najafi (ref_23) 2019; 234
ref_39
ref_15
ref_37
Cheng (ref_10) 2014; 6
Paino (ref_24) 2018; 37
Xiang (ref_31) 2021; 6
Mete (ref_2) 2022; 33
Chen (ref_4) 2010; 39
Chen (ref_6) 2022; 2022
Ren (ref_27) 2018; 17
Zhou (ref_36) 2022; 27
Jiang (ref_18) 2018; 24
Perez (ref_20) 2022; 29
Xu (ref_17) 2018; 78
Zheng (ref_35) 2023; 21
ref_1
Mariathasan (ref_19) 2018; 554
Hescot (ref_21) 2019; 104
Liu (ref_38) 2023; 41
Li (ref_16) 2017; 77
ref_5
Lenders (ref_3) 2014; 99
ref_7
Juhlin (ref_25) 2021; 32
References_xml – ident: ref_37
  doi: 10.3389/fimmu.2024.1478922
– volume: 11
  start-page: 34
  year: 2019
  ident: ref_14
  article-title: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data
  publication-title: Genome Med.
  doi: 10.1186/s13073-019-0638-6
– ident: ref_30
  doi: 10.3390/cancers17010066
– volume: 32
  start-page: 228
  year: 2021
  ident: ref_25
  article-title: Challenges in Paragangliomas and Pheochromocytomas: From Histology to Molecular Immunohistochemistry
  publication-title: Endocr. Pathol.
  doi: 10.1007/s12022-021-09675-0
– ident: ref_13
  doi: 10.1186/s13059-017-1349-1
– volume: 2022
  start-page: 5694033
  year: 2022
  ident: ref_6
  article-title: Analysis of Stemness and Prognosis of Subtypes in Breast Cancer Using the Transcriptome Sequencing Data
  publication-title: J. Oncol.
– volume: 17
  start-page: 108
  year: 2018
  ident: ref_27
  article-title: Tumor microenvironment participates in metastasis of pancreatic cancer
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0858-1
– ident: ref_5
  doi: 10.3389/fimmu.2022.796606
– volume: 33
  start-page: 90
  year: 2022
  ident: ref_2
  article-title: Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas
  publication-title: Endocr. Pathol.
  doi: 10.1007/s12022-022-09704-6
– volume: 78
  start-page: 6575
  year: 2018
  ident: ref_17
  article-title: TIP: A Web Server for Resolving Tumor Immunophenotype Profiling
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-18-0689
– volume: 104
  start-page: 2367
  year: 2019
  ident: ref_21
  article-title: Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2018-01968
– volume: 554
  start-page: 544
  year: 2018
  ident: ref_19
  article-title: TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
  publication-title: Nature
  doi: 10.1038/nature25501
– volume: 37
  start-page: 296
  year: 2018
  ident: ref_24
  article-title: HDAC2 depletion promotes osteosarcoma’s stemness both in vitro and in vivo: A study on a putative new target for CSCs directed therapy
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-018-0978-x
– ident: ref_32
  doi: 10.3390/ijms22137239
– volume: 77
  start-page: e108
  year: 2017
  ident: ref_16
  article-title: TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-0307
– volume: 12
  start-page: 453
  year: 2015
  ident: ref_11
  article-title: Robust enumeration of cell subsets from tissue expression profiles
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.3337
– ident: ref_7
  doi: 10.3390/genes13060993
– ident: ref_33
  doi: 10.3390/cancers14030467
– volume: 234
  start-page: 8381
  year: 2019
  ident: ref_23
  article-title: Cancer stem cells (CSCs) in cancer progression and therapy
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.27740
– volume: 21
  start-page: 789
  year: 2023
  ident: ref_35
  article-title: Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: Prognostic and therapeutic significance
  publication-title: J. Transl. Med.
  doi: 10.1186/s12967-023-04683-6
– volume: 27
  start-page: 167
  year: 2022
  ident: ref_36
  article-title: Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy
  publication-title: Mol. Ther. Oncolytics
  doi: 10.1016/j.omto.2022.10.005
– volume: 31
  start-page: 181
  year: 2017
  ident: ref_8
  article-title: Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.01.001
– volume: 106
  start-page: e1937
  year: 2021
  ident: ref_26
  article-title: Metastatic Pheochromocytomas and Abdominal Paragangliomas
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/clinem/dgaa982
– ident: ref_34
  doi: 10.3390/jcm10010088
– volume: 53
  start-page: 90
  year: 2018
  ident: ref_22
  article-title: Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2018.06.006
– volume: 39
  start-page: 775
  year: 2010
  ident: ref_4
  article-title: The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer
  publication-title: Pancreas
  doi: 10.1097/MPA.0b013e3181ebb4f0
– volume: 99
  start-page: 1915
  year: 2014
  ident: ref_3
  article-title: Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline
  publication-title: J. Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2014-1498
– volume: 2
  start-page: 859
  year: 2018
  ident: ref_29
  article-title: M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion
  publication-title: Blood Adv.
  doi: 10.1182/bloodadvances.2018015685
– volume: 6
  start-page: 540
  year: 2014
  ident: ref_10
  article-title: Systematic evaluation of connectivity map for disease indications
  publication-title: Genome Med.
  doi: 10.1186/s13073-014-0095-1
– volume: 120
  start-page: 2756
  year: 2019
  ident: ref_28
  article-title: Macrophage polarity in cancer: A review
  publication-title: J. Cell. Biochem.
  doi: 10.1002/jcb.27646
– ident: ref_1
  doi: 10.3390/cancers14040917
– volume: 173
  start-page: 338
  year: 2018
  ident: ref_9
  article-title: Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
  publication-title: Cell
  doi: 10.1016/j.cell.2018.03.034
– volume: 2120
  start-page: 233
  year: 2020
  ident: ref_12
  article-title: EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-0716-0327-7_17
– volume: 2016
  start-page: 9012369
  year: 2016
  ident: ref_40
  article-title: Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies
  publication-title: Mediat. Inflamm.
  doi: 10.1155/2016/9012369
– volume: 6
  start-page: 75
  year: 2021
  ident: ref_31
  article-title: Targeting tumor-associated macrophages to synergize tumor immunotherapy
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-021-00484-9
– volume: 41
  start-page: 1852
  year: 2023
  ident: ref_38
  article-title: Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2023.09.011
– ident: ref_39
  doi: 10.3389/fonc.2023.1139990
– ident: ref_15
  doi: 10.1186/s13059-016-1070-5
– volume: 24
  start-page: 1550
  year: 2018
  ident: ref_18
  article-title: Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0136-1
– volume: 29
  start-page: 533
  year: 2022
  ident: ref_20
  article-title: SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma
  publication-title: Endocr. Relat. Cancer
  doi: 10.1530/ERC-21-0392
SSID ssj0001325264
Score 2.285859
Snippet Background: Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new...
Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences or new tumor...
SourceID doaj
unpaywall
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 219
SubjectTerms Algorithms
Biological activity
Biomarkers
Cancer
Cancer therapies
Correlation analysis
Data mining
Development and progression
Drug resistance
Gene expression
Genes
Hypertension
Immune checkpoint
Immunity (Disease)
Immunology
Immunotherapy
Infiltration
Lymphocytes
Machine learning
Macrophages
Medical prognosis
Metastases
Metastasis
Mutation
Neoantigens
Network analysis
Paraganglioma
Patients
Pheochromocytoma
pheochromocytoma and paragangliomas
Prognosis
prognostic model
Regression analysis
Risk
Risk groups
RNA
RNA sequencing
Standard scores
Stem cells
Survival analysis
Tumor antigens
Tumor microenvironment
tumor stemness
Tumors
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-N7gF4QHyOwEBGQuKpamLn8wGhrdo0EKuqwaS9RY5jtxEjKW0qNP4r_kPunKRtACFe-uCPJo7Pd2f77vcDeI1erkTPIRmGdLfui8ynS0KbKxMqtGA8sCBJ55Pw7NL_cBVc7cGky4WhsMpOJ1pFnVeKzshHKHueQGOdiHeLb0NijaLb1Y5CQ7bUCvlbCzF2C_Y5IWMNYP_4ZDK92J66CB6gC9CkCgvc74-yotJb5D-Po9Bzgt3ZsVIWzP9Plb1js36Pp7y9Lhfy5ru8vt4xVqf34V7rZbKjRiwewJ4uH8LdHezBR_DzvCPGZZ-KWYPvuWKVYWOSAyys9VdSg2y8gXT-oRm6i2xMhB5tCB2jc1w2XVYUr1esmCxz9p5STjT7SEnEFF5lC6dLuhGq2UWx-sIsJC7FKNk_YUXJpnNdqTmFBqqbmkKWmk745JmkRGMqegyXpyefx2fDlr9hqAIe1Pgbcs9XEffzLIxyOjDhSibaxEJI4ook3g-iOOdCKsGVCaNEos9gpJvEJszEExiUVamfAjNengQ8D9xMSV_mXEqpY1eHLtdBGOvYgVE3X-migelIcXtDM5z-fYYdOKZp3bQmmG1bUC1nabtq0yhU2pjYiAS9GCNERk_2XC18GXkqyxx4Q0KRkjLAL6dkm9OAL02wWukR6kvcwiSJ78BhryUuYtWv7sQqbZXIKt2KvAOvNtXUkwLjSl2tbRtOCEBe4MBBI4WbIfkWPjLG3nFPPntj7teUxdxCjHvo1-OYPQfcjSj_54d99u-hPIc7nCiUCRXAO4RBvVzrF-jX1dnLdrH-AgU_Uss
  priority: 102
  providerName: ProQuest
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdQ9wA8ML7JGMhISDx1S_yV5LFUTAOxUQGVxlNkO84abSRTmwpt_xX_IXdOWpqB0Hjpg-1rcvb5fBff_Y6Q12DlarAc0qHCu3XBjcBLQp8royycYEx6kKSjY3U4FR9O5EnnKGIuzMb9PQd3fN-UtfsNzBcxkEmGKJ9bSoLtPSBb0-PJ6JuvIAeuseRStGnA_yDunUAeqP9PdbxxHl2Plby9rC705Q99fr5xEB1sk08rFtr4k7O9ZWP27NU1dMeb83if3OtsUjpqhegBueWqh-TuBlLhI_LzaFVGl34pT1s00AWtCzpGqYHGxn1HpUnHawDoK0fBuKRjLP_RBdxR_OpLJ_Mao_vKBdVVTt9jgoqjHzHlGIOxfONkjvdHDf1cLs6oB9DFiCb_J7Ss6GTmajvDQEJ72WCAU0sETz7VmJaMTY_J9ODd1_HhsKv2MLSSyQZ-FYuEjZnIjYpz_LzCrE5dkXCusbIkVgnBguiMa8uZLVScarAwCh2mSaEMf0IGVV25Z4QWUZ5KlsvQWC10zrTWLgmdCpmTKnFJQPZXEpBdtKAeGThDuBjZ3xcjIG9RUNajEZTbN8A6Zt0ez2JlXVEkBU_B5ik4N_jkKHRc6DiyxgTkDYpZhqoDZs7qLgMCXhpBuLIRaFdweNJUBGS3NxK2vO13rwQ161TOIgPlHHGYw5QH5NW6GykxjK5y9dKPYYgXFMmAPG3les2S8GCTCVAnPYnv8dzvqcqZBySPwAsAnqOAhOvNccOJ3fl_kufkDsMizIgrEO2SQTNfuhdgGTbmZacOfgGbimcU
  priority: 102
  providerName: Unpaywall
Title Molecular Signatures of Cancer Stemness Characterize the Correlations with Prognosis and Immune Landscape and Predict Risk Stratification in Pheochromocytomas and Paragangliomas
URI https://www.ncbi.nlm.nih.gov/pubmed/40150683
https://www.proquest.com/docview/3181356293
https://www.proquest.com/docview/3182480115
https://pubmed.ncbi.nlm.nih.gov/PMC11939611
https://doi.org/10.3390/bioengineering12030219
https://doaj.org/article/76ceff8f39614f33bd2aa10e34a71cbb
UnpaywallVersion publishedVersion
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2306-5354
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325264
  issn: 2306-5354
  databaseCode: KQ8
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2306-5354
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325264
  issn: 2306-5354
  databaseCode: DOA
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 2306-5354
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325264
  issn: 2306-5354
  databaseCode: ABDBF
  dateStart: 20180301
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2306-5354
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325264
  issn: 2306-5354
  databaseCode: M~E
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2306-5354
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325264
  issn: 2306-5354
  databaseCode: RPM
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2306-5354
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325264
  issn: 2306-5354
  databaseCode: BENPR
  dateStart: 20140301
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Technology Collection
  customDbUrl:
  eissn: 2306-5354
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001325264
  issn: 2306-5354
  databaseCode: 8FG
  dateStart: 20140301
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/technologycollection1
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgOQAHxJvAUhkJiVPVxM7Lx7ZsWRBbRQuVllPkOPY2YklWbSq0_Cv-ITNOGhJAggOXRvWjjT3jmbE98w0hL8HKlWA5iHGId-s-z3y8JLSxMqECDcYCC5J0sgyPV_67s-Csl-oLfcIaeOBm4iZRqLQxseECFInhPMuZlJ6ruS8jT2UZSl83Fr3NlD1d4SwAVd-EBHPY10-yotI_Ef48BszNEF6np40saP_vormnm371m7y5Ky_l1Vd5cdFTSou75E5rTdJpM4p75Jou75PbPYzBB-T7yT4BLv1QnDc4nltaGTpHekNhrb-guKPzDrr5m6ZgFtI5Ju5oXeUontfSZFOhX16xpbLM6VsMLdH0PQYLoxuVLUw2ePNT09Ni-5la6Fv0RbI_QouSJmtdqTW6AKqrGl2Tmk7wz-cSA4qx6CFZLY4-zo_HbZ6GsQpYUMNnyDxfRczPszDK8WCEKSm0iTmXmBMS83tgKnPGpeJMmTASEmwDI10RmzDjj8hBWZX6CaHGy0XA8sDNlPQlklrq2NWhy3QQxjp2yGRPr_SygeNIYRuDFE7_TGGHzJCsXWuE07YFwGRpy2Tp35jMIa-QKVJc9DBzSraxC_DSCJ-VTkEuwlZFCN8hh4OWsFjVsHrPVmkrLLYpiFWPwxwK7pAXXTX2RAe4Ulc724Yh0o8XOORxw4XdkHwLExlD73jAn4MxD2vKYm2hxD2w32HMnkPcjpX_cWKf_o-JfUZuMUyojBgB3iE5qDc7_RysvDobkevx4s2I3JjOXs8W8JwdLZPTkV3m8G21TKaffgCb7FuU
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6V9lA4IN4YCiwSiFMUe3ft2IcKtaFVQpMoKq3Um1mv14nV1g6Joyr8K_4Av42ZtZ0HIMSllxz2YWc9s_PYnfmGkHdg5UqwHIKGh3frgkcCLwlNroynQIMx14Ak9Qde51x8vnAvtsjPOhcGwyprmWgEdZwrPCNvAu85HJR1wD9OvjWwahTertYlNGRVWiHeNxBjVWLHiV7cgAs32-9-Anq_Z-z46KzdaVRVBhrKZW4Bvx5zhGoxEUdeK0a3nikZ6MTnXGJFQ6xOgYW4GZeKM5V4rUCCZkukHfiJF3F47h2yI7gIwPnbOTwaDE9XpzycwUxRpiZzHtjNKM31CmnQYbDJGML8rGlFUzzgTxWxpiN_j9_cnWcTubiRV1dryvH4AblfWbX0oGTDh2RLZ4_IvTWsw8fkR78uxEu_pKMST3RG84S2ke-gsdDXKHZpewkh_V1TME9pGwuIVCF7FM-N6XCaY3xgOqMyi2kXU1w07WHSMoZzmcbhFG-gCnqazi6pgeDFmCjzEJpmdDjWuRpjKKJaFBgiVU6CN48kJjZj0xNyfiuUfEq2szzTzwlNnDhwWezakZJCxkxKqX1bezbTrudr3yLNml7hpIQFCcGdQgqHf6ewRQ6RrMvRCOttGvLpKKykRNjylE4SP-EBWE0J5xG-2bE1F7LlqCiyyAdkihCFD3w5JascCvjTCOMVHoB8BpcpCIRF9jZGgtBQm901W4WV0JqFqy1mkbfLbpyJgXiZzudmDEPEIce1yLOSC5dLEgau0ofZ_gZ_bqx5sydLxwbS3AE_AtbsWMResvJ_ftgX_17KG7LbOev3wl53cPKS3GVYvhkRCZw9sl1M5_oV2JRF9LrauJR8vW1Z8QvsDY2l
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwEB4ti8TjgHgTWMBIIE5VEzvPA0JLl7JlH6qAlfYWHMdpI5aktKlW5V9x5dcx4yR9AEJc9tKDH0mdGc_DnvkG4DlauRIth6jj0926KxKXLglNroyvUINxz4AkHR37-yfu-1PvdAt-trkwFFbZykQjqNNS0Rl5F3nPEaisI9HNmrCI4V7_9eRbhypI0U1rW06jZpEDvThH9232arCHtH7Bef_tp95-p6kw0FEe9yr89bnjqoC7aeIHKbn0XMlIZ6EQkqoZUmUKKsLNhVSCq8wPIolaLZN2FGZ-IvC5l-ByQCjulKXef7c63xEc57l1UrIQkd1N8lKvMAYdjtuLE8DPmj40ZQP-VA5r2vH3yM2r82IiF-fy7GxNLfZvwo3GnmW7NQPegi1d3IbrayiHd-DHUVuCl33MRzWS6IyVGesRx2Fjpb-SwGW9JXj0d83QMGU9Kh3SBOsxOjFmw2lJkYH5jMkiZQNKbtHskNKVKZDLNA6ndPdUsQ_57Asz4LsUDWUewvKCDce6VGMKQlSLioKj6kn45pGklGZqugsnF0LHe7BdlIV-ACxz0sjjqWcnSroy5VJKHdrat7n2_FCHFnRbesWTGhAkRkeKKBz_ncIWvCGyLkcToLdpKKejuJEPceArnWVhJiK0lzIhEnqzY2vhysBRSWLBS2KKmMQOfjklm-wJ_NME4BXvomRGZymKXAt2NkaiuFCb3S1bxY24msWrzWXBs2U3zaQQvEKXczOGE9aQ41lwv-bC5ZJcA1QZ4uxwgz831rzZU-RjA2buoAeBa3YssJes_J8f9uG_l_IUrqCEiA8HxweP4Bqnus0EReDswHY1nevHaExWyROzaxl8vmgx8QsmZIs_
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdQ9wA8ML7JGMhISDx1S_yV5LFUTAOxUQGVxlNkO84abSRTmwpt_xX_IXdOWpqB0Hjpg-1rcvb5fBff_Y6Q12DlarAc0qHCu3XBjcBLQp8royycYEx6kKSjY3U4FR9O5EnnKGIuzMb9PQd3fN-UtfsNzBcxkEmGKJ9bSoLtPSBb0-PJ6JuvIAeuseRStGnA_yDunUAeqP9PdbxxHl2Plby9rC705Q99fr5xEB1sk08rFtr4k7O9ZWP27NU1dMeb83if3OtsUjpqhegBueWqh-TuBlLhI_LzaFVGl34pT1s00AWtCzpGqYHGxn1HpUnHawDoK0fBuKRjLP_RBdxR_OpLJ_Mao_vKBdVVTt9jgoqjHzHlGIOxfONkjvdHDf1cLs6oB9DFiCb_J7Ss6GTmajvDQEJ72WCAU0sETz7VmJaMTY_J9ODd1_HhsKv2MLSSyQZ-FYuEjZnIjYpz_LzCrE5dkXCusbIkVgnBguiMa8uZLVScarAwCh2mSaEMf0IGVV25Z4QWUZ5KlsvQWC10zrTWLgmdCpmTKnFJQPZXEpBdtKAeGThDuBjZ3xcjIG9RUNajEZTbN8A6Zt0ez2JlXVEkBU_B5ik4N_jkKHRc6DiyxgTkDYpZhqoDZs7qLgMCXhpBuLIRaFdweNJUBGS3NxK2vO13rwQ161TOIgPlHHGYw5QH5NW6GykxjK5y9dKPYYgXFMmAPG3les2S8GCTCVAnPYnv8dzvqcqZBySPwAsAnqOAhOvNccOJ3fl_kufkDsMizIgrEO2SQTNfuhdgGTbmZacOfgGbimcU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+Signatures+of+Cancer+Stemness+Characterize+the+Correlations+with+Prognosis+and+Immune+Landscape+and+Predict+Risk+Stratification+in+Pheochromocytomas+and+Paragangliomas&rft.jtitle=Bioengineering+%28Basel%29&rft.au=Li%2C+Lei&rft.au=Liu%2C+Shuangyu&rft.au=Guo%2C+Zeqi&rft.au=Tang%2C+Yueming&rft.date=2025-02-21&rft.issn=2306-5354&rft.eissn=2306-5354&rft.volume=12&rft.issue=3&rft.spage=219&rft_id=info:doi/10.3390%2Fbioengineering12030219&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_bioengineering12030219
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2306-5354&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2306-5354&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2306-5354&client=summon